Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a+/- mouse model of Dravet syndrome
A purified preparation of cannabidiol (CBD), a cannabis constituent, has been approved for the treatment of intractable childhood epilepsies such as Dravet syndrome. Extensive pharmacological characterization of CBD shows activity at numerous molecular targets but its anticonvulsant mechanism(s) of...
Main Authors: | Lyndsey L. Anderson, Dilara A. Bahceci, Nicole A. Hawkins, Declan Everett-Morgan, Samuel D. Banister, Jennifer A. Kearney, Jonathon C. Arnold |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879440/?tool=EBI |
Similar Items
-
Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a+/- mouse model of Dravet syndrome.
by: Lyndsey L Anderson, et al.
Published: (2023-01-01) -
Ictal vocalizations in the Scn1a+/− mouse model of Dravet syndrome
by: Lyndsey L. Anderson, et al.
Published: (2023-09-01) -
Heat-induced seizures, premature mortality, and hyperactivity in a novel Scn1a nonsense model for Dravet syndrome
by: Anat Mavashov, et al.
Published: (2023-05-01) -
Switching from zonisamide to perampanel improved the frequency of seizures caused by hyperthermia in Dravet syndrome: a case report
by: Kazuhiro Horiuchi, et al.
Published: (2024-01-01) -
Neurodevelopmental defects in Dravet syndrome Scn1a+/− mice: Targeting GABA-switch rescues behavioral dysfunctions but not seizures and mortality
by: Lara Pizzamiglio, et al.
Published: (2025-04-01)